Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Oncor study of bladder cancer microsatellite DNA test to begin in several months.

This article was originally published in The Gray Sheet

Executive Summary

ONCOR PMA FOR BLADDER CANCER MICROSATELLITE DNA TEST may be submitted as early as 1997 but more likely will not be ready until 1998 due to the pursuit of a patient screening indication for the test, the Gaithersburg, Maryland company says. Oncor is hoping to pursue approval of the test for screening in high-risk populations, which would require more extensive follow-up data than a patient monitoring claim, the company says. However, the test is still in early stages of development, Oncor notes, and the final form of the premarket approval application has yet to be determined.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT005459

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel